Original research article BACKGROUND: Elevated lipoprotein(a) [Lp(a)] is a prevalent, independent cardiovascular risk factor, but the underlying mechanisms responsible for its pathogenicity are poorly defined. Because Lp(a) is the prominent carrier of proinflammatory oxidized phospholipids (OxPLs), part of its atherothrombosis might be mediated through this pathway.
in atherogenesis now has been established by both meta-analyses of epidemiologic studies and genome-wide association and mendelian randomization studies, showing a strong, independent, and likely causal relationship between Lp(a) and myocardial infarction, stroke, peripheral artery disease, and calcific aortic valve stenosis. 1, 2 Despite evidence of causality and the fact that onefifth of the general community has elevated Lp(a) levels >50 mg/dL, 3 Lp(a) is not measured routinely in clinical risk assessment. This reluctance seems to be due to a lack of understanding of the pathophysiologic mechanisms by which Lp(a) mediates cardiovascular disease (CVD), as well as the lack of specific therapeutic interventions to potently lower Lp(a) levels. 4 Consistent with known mechanisms of atherogenicity of LDL, the atherogenic capacity of could in part reflect the response-toretention phenomenon of an apoB-containing particle. 5 The disproportionately large impact of Lp(a) on CVD risk compared with LDL, however, implies that additional pathogenic pathways need to be considered. 6 During the past decade, a large body of experimental and clinical evidence has documented that Lp(a) is the main lipoprotein carrier of phosphocholine-containing oxidized phospholipids (OxPLs) in plasma, [7] [8] [9] which has led to the hypothesis that a major component of the risk mediated by Lp(a) is its OxPL content. 10 OxPL is recognized as a danger-associated molecular pattern by pattern recognition receptors on innate immune cells, leading to a wide range of proinflammatory and plaquedestabilizing processes. [11] [12] [13] In epidemiologic studies, the level of OxPL on apoB-containing lipoproteins (OxPL-apoB), which predominantly reflects Lp(a)-associated OxPL, was found to be highly predictive of future CVD risk. 14, 15 Most recently, another link between Lp(a), OxPL, and inflammation was discovered, showing that the risk of Lp(a) and OxPL-apoB in mediating coronary atherogenesis and cardiovascular events was conditional on an inflammatory interleukin (IL-1) haplotype. 16 Here, we report that subjects with elevated plasma Lp(a) levels are characterized by increased inflammatory activity of the arterial wall and an enhanced inflammatory response of circulating monocytes, for which OxPLs carried by Lp(a) were identified as obligatory intermediates. These findings indicate a novel link between Lp(a), its associated OxPLs, and accelerated atherogenesis in humans.
MethODs study subjects
This was a single-center study in subjects with elevated Lp(a) and subjects with normal Lp(a) matched for age, sex, and body mass index. Exclusion criteria were active smoking, history of clinically manifest CVD or diabetes mellitus, and lipidlowering therapies, including statins. Each subject provided written informed consent. The study and radiation exposure (<10 mSv in total) were approved by the local institutional review board and conducted according to the principles of the International Conference on Harmonization-Good Clinical Practice guidelines.
Biochemical Measurements
EDTA plasma obtained through venous blood samples was taken after overnight fasting and stored with standardized protocols. Plasma Lp(a), total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride levels were analyzed with commercially available enzymatic methods. LDL cholesterol levels were calculated with the Friedewald equation and subsequently corrected for Lp(a)-cholesterol: LDL cholesterol−[Lp(a) in mmol/L×0.3]. 17 OxPLs on OxPL-apoB and on apo(a) [OxPLapo(a)] were measured as follows: ApoB-100 and apo(a) were captured on microtiter wells using appropriate antibodies, and the content of OxPL was quantified by monoclonal antibody E06 and reported as nanomoles per liter, as previously described. 10 
Magnetic resonance imaging
Magnetic resonance images were obtained with a 3.0-T wholebody scanner (Ingenia, Philips Medical Systems, Best, the Netherlands) using an 8-channel dedicated bilateral carotid clinical Perspective What is new?
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ORIGINAL RESEARCH ARTICLE 613 artery coil (Shanghai Chenguang Medical Technologies, Shanghai, China). The normalized wall index (mean wall area/ outer wall area) was calculated 18 by a blinded experienced reader at the core laboratory using semiautomated measurement software (VesselMass, Leiden, the Netherlands).
Positron emission tomography/computed tomographic imaging
Positron emission tomography (PET)/computed tomographic (CT) scans were performed on a dedicated scanner (Philips, Best, the Netherlands). 19 All subjects fasted for at least 6 hours before infusion of 18 F-fluorodeoxyglucose uptake ( 18 F-FDG; 200 MBq). After 90 minutes, subjects underwent PET imaging initiated with a low-dose non-contrast-enhanced CT for attenuation correction and anatomic coregistration. PET/CT images were analyzed by blinded readers using OsiriX 20 (Geneva, Switzerland The target-to-background ratio was calculated from the ratio of arterial standardized uptake value and venous background activity, as described previously. 19 
single-Photon emission ct/ct imaging
Single-photon emission CT (SPECT)/CT scans were performed at 3, 4.5, and 6 hours after infusion of 99m Tc-labeled autologous peripheral blood mononuclear cells (PBMCs; 200 MBq) on a dedicated scanner (Symbia T16, Siemens, Erlangen, Germany). 21 In each subject, ≈20×10 6 PBMCs were isolated and labeled with 99m Tc (1100 MBq/2 mL). Single-photon emission CT/CT images were analyzed by blinded readers using OsiriX. 21 Accumulation of labeled PBMCs in the arterial wall was quantified by the ratio of the averaged maximum counts in the artery divided by the averaged mean counts in the blood, reported as the arterial wall-to-blood-ratio. 21 
Flow cytometry
Blood samples were collected into K3EDTA BD Vacutainer1 (BD Biosciences, San Jose, CA) tubes, after which 50 μL whole blood was added to each flow cytometry tube plus the appropriate amounts of each antigen-specific monoclonal antibody, defined after titration of the dose recommended by the manufacturers. The online-only Data Supplement provides detailed information. In the monocyte assays, Lp(a), LDL, and HDL were isolated from 3.5 mL plasma from subjects with either high or normal Lp(a) levels by KBr-density gradient ultracentrifugation; plasma density was adjusted to d=1.25 g/mL with solid KBr (0.385 g/ mL plasma); a discontinuous gradient was formed by carefully layering 2 mL of d=1.225 g/mL KBr solution, followed by 4 mL of d=1.100 g/mL KBr solution; and a top layer of 3 mL of d=1.006 g/mL KBr solution was added. The samples were centrifuged for 20 hours at 10°C at 29 000 rpm in an SW-41 Ti rotor (Beckman Coulter Inc). The LDL, Lp(a), and HDL fractions were sliced out and dialyzed against PBS. LAL assay showed negligible endotoxin levels (<0.05 EU/mL) in the isolated fractions. For the Western immunoblots, Lp(a) was purified from the lipid apheresis eluate of a single donor undergoing LDL apheresis with high Lp(a) levels (140 mg/dL) and 16 KIV and 18 KIV repeats. The apheresis eluate was subjected to ultracentrifugation in NaBr, and the 1.08>d>1.06 g/mL fraction was collected. This fraction was applied to an SW-400 gel filtration column, which was eluted in 0.5-mL fractions. Each fraction was assayed for the presence of apo(a) and apolipoprotein A-I by ELISA. The fractions containing apo(a) but not apolipoprotein AI were pooled, buffer exchanged into PBS, and concentrated with the use of Amicon centrifugal filter units (Millipore). Apo(a) was dissociated from Lp(a) with the methods described previously. 23, 24 Briefly, the solution containing Lp(a) was adjusted to a final concentration of 100 mmol/L ACA and 2 mmol/L dithiothrietol and incubated at room temperature for 1 hour. The reaction mixture was adjusted to a density of 1.3 g/mL with NaBr, and the solution was centrifuged at 50 000 rpm to separate apo(a) from the LDL released by reduction and intact Lp(a).
Western immunoblot
SDS-PAGE of apo(a), Lp(a), and LDL (100 ng protein), in reducing (with β-mercaptoethanol) and nonreducing conditions, was carried out with 3% to 8% gradient polyacrylamide gels in Tris-acetate SDS running buffer. Proteins were transferred to a polyvinylidene fluoride membrane, which was blocked with 3% BSA in PBS-Tween. Membranes were then incubated with biotinylated LPA4 (0.004 mg/mL), biotinylated E06 (0.004 mg/mL), or MB47 (0.006 mg/mL) probing for apo(a), OxPL, and human apoB-100, respectively. Protein detection was performed with streptavidin conjugated to horseradish peroxidase from R&D Systems (Minneapolis, MN) and visualized with ECL (Amersham).
Detection of OxPl by liquid chromatographytandem Mass spectrometry
To document the presence of phosphocholine-containing OxPL in Lp(a) purified by ultracentrifugation, Lp(a) was isolated from 3 donors. Details of the liquid chromatography-tandem mass spectrometry procedures are given in the online-only Data Supplement.
transendothelial Migration assay
Human aortic endothelial cells were cultured on a fibronectincoated glass cover to confluence and stimulated overnight (ie, 12 hours) with tumor necrosis factor-α (TNFα; 10 ng/mL). 25 Monocytes (1×10 6 cells/mL) were added to the human arterial endothelial cell monolayer for 30 minutes in a humidified atmosphere of 5% CO 2 at 37°C and fixed with 3.7% formaldehyde (Sigma-Aldrich, Zwijndrecht, the Netherlands). After fixation, multiple images were recorded with a Zeiss Axiovert 200 microscope (Plan-apochromat 10×/0.45 M27 Zeiss objective; Carl Zeiss Inc, Jena, Germany) and analyzed with Image-J software. 26 After treatment and fixation in 3.7% formaldehyde in PBS (+1 mmol/L CaCl 2 , 0.5 mmol/L MgCl 2 ), cells were permeabilized in PBS plus 0.1% Triton-X100 for 10 minutes, stained for nuclei and F-actin for 45 minutes, washed, and stored in PBS (+1 mmol/L CaCl 2 , 0.5 mmol/L MgCl 2 ) until imaged with a confocal laser-scanning microscope (LSM510 META, Carl Zeiss MicroImaging) with a Zeiss Plan-Apochromat, 63×/1.40 oil objective. Monocyte motility was determined by plating freshly isolated monocytes into fibronectin (Sanquin Reagents, the Netherlands) -coated Laboratory-Tek Chambers (Thermo-Scientific, Rochester, NY) containing HEPES buffer plus 1 mmol/L CaCl 2 plus 0.5% vol/vol human albumin and 0.1% wt/ vol glucose. Videos were acquired with a wide-field microscope (Axio Observer Z1, Carl Zeiss MicroImaging) equipped with a humidified atmosphere climate chamber with 5% CO 2 and 37°C and analyzed with the Tracking Tool (Gradientech, Uppsala Science Park, Uppsala, Sweden).
in Vitro Monocyte Priming and challenge assay
Monocytes were isolated from PBMCs by adhering 5×10 6 PBMCs/mL to polystyrene for 1 hour at 37°C, 5% CO 2 in 96or 6-well culture plates (Corning, NY, New York). Nonadherent cells were removed by washing 3 times with warm PBS. Monocytes were cultured in RPMI 1640 Dutch-modified culture medium (Life Technologies/Invitrogen, Breda, the Netherlands) supplemented with 10 mmol/L glutamine (Invitrogen), 10 µg/ mL gentamicin (Centraform), 10 mmol/L pyruvate (Invitrogen), and 10% pooled human plasma. The monocytes were primed for 24 hours with RPMI, β-glucan (5 μg/mL), isolated Lp(a) (0.5-250 µg/mL), LDL (10 μg/mL), HDL (10 μg/mL), r-apo(a) constructs (8K-IV 0.001-0.5 µg/mL; 17K and 17KΔLBS10 0.1 µg/mL), OxPAPC (0.05-10 µg/mL), or 10% plasma from subjects with high or normal Lp(a) levels (before and after apoB precipitation of the apoB-containing lipoprotein fraction with polyethylene glycol 8000, Sigma P-2139 27 ), after which the cells were washed and incubated in supplemented culture medium for 6 days. In inhibition experiments using E06 (1 nmol/L) or IgM control (1 nmol/L), stimuli were preincubated with the inhibitors 1 hour before the stimuli were added to the cells. After 6 days of rest in supplemented RPMI medium, cells were exposed to medium alone, 10 µg/mL Pam3Cys, or 10 ng/mL lipopolysaccharide. After 24 hours of incubation, supernatants were collected and stored at −20°C. Production of cytokines was measured in supernatants by ELISA according to the manufacturer's instructions (TNFα; R&D Systems) and IL-6 (Sanquin, Amsterdam, the Netherlands) or the human inflammatory cytokine Cytometric Bead Array according to the manufacturer's instructions (BD Biosciences, 551811).
statistical analysis
Data are presented as mean (standard deviation) or the median (minimum-maximum) for continuous variables and as a number (percentage) for categorical variables. To examine the difference in clinical characteristics, imaging parameters, and ex vivo monocyte phenotype and function between subjects with elevated or normal Lp(a), we performed the Student t test or Mann-Whitney U test for normal and nonnormal distributed variables, respectively. Normality was examined by means of inspection of histograms and the Shapiro-Wilk test. Variances in both groups were examined and tested for similarity with the Levene test for variance. To assess the differences in PBMC accumulation as imaged with single-photon emission CT, a linear mixed model for repeated measurements was applied ( Figure 1D-1F ). In vitro monocyte experiments were performed at least 6 times and analyzed with the Wilcoxon signed-rank test. A 2-sided value of P<0.05 was considered statistically significant. All data were analyzed with Prism version 5.0 (GraphPad Software, La Jolla, CA) or SPSS version 21.0 (SPSS Inc, Chicago, IL).
resUlts increased arterial Wall inflammation in subjects With elevated lp(a)
To determine whether Lp(a) influences arterial wall inflammation, we included subjects with elevated Lp(a) levels (mean, 108 mg/dL; range, 50-195 mg/dL; n=30) or normal Lp(a) levels (mean, 7 mg/dL; range 2-28 mg/ dL; n=30) matched for age, sex, and body mass index ( Table 1) . None of the subjects were currently smoking, had a history of clinically manifest CVD or diabetes mellitus, or used lipid-lowering therapies such as statins. Aside from Lp(a) levels, subjects did not differ in blood pressure, non-Lp(a) lipoprotein profile, or circulating leukocytes ( Table 1) . As expected, subjects with elevated Lp(a) exhibited significantly higher levels of OxPL-apoB and, specifically, OxPL on apo(a) lipoproteins [OxPLapo(a); Table 1 ). The normalized wall index of the carotids, as assessed with magnetic resonance imaging, 18 was not significantly different between groups (Table 1 and Figure IIA in the online-only Data Supplement).
PET/CT imaging was performed to image arterial wall 18 F-FDG as a marker of arterial wall inflammation. 28 In subjects with elevated Lp(a), arterial wall 18 F-FDG uptake, quantified as the target-to-background ratio, was significantly higher compared with subjects with normal Lp(a) ( Figure 1A ) in both the carotid arteries ( Figure 1B ) and aorta ( Figure 1C ). Of note, the inflammatory activity in subjects with elevated Lp(a) did not correlate to arterial wall dimensions (normalized wall index) as assessed with magnetic resonance imaging ( Figure IIB in the online-only Data Supplement).
In view of the intricate relation between resident arterial wall macrophages and circulating monocytes, 29 we subsequently investigated the impact of elevated Lp(a) on circulating immune cells in vivo. We used an imaging approach to monitor the trafficking of 99m Tc-labeled autologous PBMCs to the arterial wall using single-photon emission CT with CT. 21 PBMCs were found to accumulate at a substantially higher rate in the arterial wall within 3 to 6 hours after reinfusion in subjects with elevated Lp(a) compared with those with normal Lp(a) ( Figure 1D ). The arterial wall-to-blood pool ratio 21 values were sig-nificantly higher in subjects with elevated Lp(a) in both the carotid arteries ( Figure 1E ) and aorta ( Figure 1F ). Collectively, these in vivo imaging studies indicate that subjects with elevated Lp(a) levels have increased arterial inflammatory activity, which coincides with more autologous immune cell accumulation in their arterial wall. Furthermore, there is a strong correlation between the target-to-background ratio indexes from PET/CT imaging and the arterial wall-to-blood ratio values from PMBC imaging and respective Lp(a) plasma levels ( Table 2 ).
Monocytes increasingly Migrate in subjects With elevated lp(a)
We next questioned whether the increased arterial wall immune cell accumulation was preceded by an intrinsic cellular activation leading to enhanced migration. To this end, we analyzed adhesion and migration markers of blood monocytes in subjects with elevated versus normal Lp(a) using flow cytometry (gating strategy in Figure IIIA in the online-only Data Supplement). 30 Monocytes from subjects with elevated Lp(a) expressed more C-C chemokine receptor type 7, L-selectin (also described as the cluster of differentiation 62 ligand), and integrin-α and -β chains, CD11b, CD11c, and CD29 31 (Figure 2A) , for which the last 2 showed a (borderline) significant correlation with the Lp(a) plasma levels (Table 2) . To evaluate the functional relevance of increased expression of adhesion and migration markers, we performed transendothelial migration experiments 25 with monocytes isolated from subjects with and without elevated Lp(a). Twelve hours before the migration assay was performed, human arterial endothelial cells were stimulated with TNFα to mimic dysfunctional endothelium. Freshly isolated monocytes of subjects with elevated Lp(a) showed a 3-fold higher transendothelial migration rate compared with monocytes isolated from subjects with normal Lp(a) ( Figure 2B ). Staining of the nucleus and F-actin illustrated that monocytes derived from subjects with elevated Lp(a) have augmented spreading and adhesion compared with monocytes of subjects with normal Lp(a) ( Figure 2C ). In addition, monocytes of subjects with elevated Lp(a) also showed higher motility when plated on fibronectincoated surfaces (Movie I in the online-only Data Supplement), lending additional support to an increased transmigratory tendency.
Thus, in subjects with elevated Lp(a), circulating monocytes exhibit an enhanced capacity to adhere and transmigrate the endothelium. Whereas generalized markers of inflammation such as plasma levels of Creactive protein do not relate to Lp(a) levels, a number of inflammatory markers measured on the monocytes of the subjects are proportional to their Lp(a) levels ( Table 2 ).
atherogenic Monocyte response in subjects With elevated lp(a)
In addition to migration markers, monocytes of subjects with elevated Lp(a) expressed increased levels of the scavenger receptors CD36 and SRA ( Figure 2D ), also correlating to Lp(a) plasma levels (Table 2) , whereas the expression of other receptors such as CD163, CD200R, and CD206 was not different ( Figure 2D ). To assess whether this activated phenotype also translated to an enhanced inflammatory response, we performed a challenge assay using Toll-like receptor (TLR) ligands. After an overnight stimulation with a TLR2 ligand (Pam-3Cys), monocytes isolated from subjects with elevated Lp(a) produced higher levels of TNFα, IL-1β, and IL-6 ( Figure 2E-2G) . Conversely, the production of IL-10 was lower ( Figure 2H Data are presented as mean±SD, n (%), or median (minimummaximum). ALT indicates alanine transaminase; apo(a), apolipoprotein(a); apoB, apolipoprotein B-100; AST, aspartate transaminase; BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; HbA 1c , hemoglobin A 1c ; HDL-C, high-density lipoprotein cholesterol; LDL-C, lowdensity lipoprotein cholesterol; Lp(a), lipoprotein(a); NWI, normalized wall index; OxPL, oxidized phospholipid; SBP, systolic blood pressure; TChol, total cholesterol; and WBC, white blood cell count. To address priming by Lp(a) or some associated component found in the plasma of subject with elevated Lp(a), we performed a series of in vitro studies in which we analyzed the ability of various plasma components to activate monocytes. As a positive control for monocyte activation, we used β-glucan, a cell wall component of Candida albicans because we have demonstrated extensively that β-glucan induces a long-lasting proinflammatory phenotype in monocytes. 32 First, priming of healthy monocytes with plasma from subjects with high Lp(a) for 24 hours, with a subsequent washout and resting period, increased the production of TNFα and IL-6 after an overnight challenge with the TLR2 and TLR4 ligands Pam3Cys and lipopolysaccharide, respectively ( Figure 3A and 3B and Figure VIA and VIB in the online-only Data Supplement), whereas normal Lp(a) plasma did not activate monocytes. Lipid depletion of the above plasma profoundly decreased the cytokine production of the in-origin high Lp(a) plasma, indicating that a lipophilic particle might be responsible for the observed effect ( Figure 3A and 3B and Figure VIA and VIB in the online-only Data Supplement).
In line with the difference in Lp(a) levels between both plasmas, priming of healthy monocytes with purified Lp(a) for 24 hours induced an increased production of TNFα and IL-6 at day 7 after an overnight TLR challenge ( Figure 3C-3F Next, we assessed the effects of the main components of Lp(a) separately using isolated LDL, apo(a) separated from Lp(a), and r-apo(a) constructs containing various numbers of kringles. 9 Whereas priming with LDL had no prolonged effects on monocytes (Figure 3G and 3H and Figure VIG and VIH in the onlineonly Data Supplement), priming with an 8K-IV r-apo(a) construct elicited an enhanced cytokine response in healthy donor monocytes at day 7 after overnight stimulation with TLR ligands ( Figure 3I and 3J and Figure  VII and VIJ) .
In view of the role of Lp(a) as a carrier of OxPL, 7-9 we hypothesized an important role for OxPL in monocyte activation. In support of this concept, we show via immunoblotting that both Lp(a) and apo(a) contain OxPL, whereas LDL isolated from the same plasma as Lp(a) does not ( Figure 4A ). To further demonstrate the role of OxPL in mediating the activation of monocytes, we used the monoclonal antibody E06, which binds to the phosphocholine moiety of OxPL and potently inhibits their proinflammatory properties but does not bind to native, non-OxPLs. [33] [34] [35] Whereas the 8K-IV apo(a) construct, containing covalently bound OxPL, 9 potently activated monocytes ( Figure 3I and 3J and Figure VII and VIJ in the online-only Data Supplement), preincubation of the 8K-IV construct with E06 inhibited its priming effects ( Figure 4B and 4C and Figure VIK and VIL in the onlineonly Data Supplement).
The role of OxPL was further validated using 2 additional constructs consisting of 17K but varying in the functionality of the lysine binding site (LBS) on kringle IV type 10, which in turn is related to the ability of the apo(a) constructs to have bound covalently OxPL. 9, 36 Thus, 17K is an r-apo(a) construct with an intact LBS that has bound covalently OxPL, whereas 17KΔLBS10 has a mutated LBS and lacks immunologically detected OxPL. 9, 36 Consistent with our previous findings with Lp(a), priming with 17K induced a state of increased responsiveness in monocytes, whereas such effects were absent with the mutant 17KΔLBS10 ( Figure 4D and 4E and Figure  VIM and VIN in the online-only Data Supplement). Finally, we show that short-term priming with purified OxPAPC, a mixture of OxPL, also results in a dose-dependent enhanced cytokine production at day 7 in response to an overnight challenge with TLR ligands ( Figure 4F and 4G and Figure VIO and VIP in the online-only Data Supplement).
Collectively, these data show that subjects with elevated Lp(a) exhibit increased arterial wall inflammation coinciding with an increased responsiveness of monocytes in which OxPLs carried by Lp(a) are obligatory mediators.
DiscUssiOn
In this translational work, we provide evidence in support of the concept that proinflammatory OxPLs are major contributors to the atherogenicity of Lp(a) by showing that (1) subjects with elevated Lp(a) have increased arterial inflammation in vivo, (2) monocytes isolated from subjects with elevated Lp(a) remain in a long-lasting activated state ex vivo, and (3) Lp(a) elicits the proinflammatory response in healthy monocytes in vitro, an effect markedly attenuated by removing or inactivating OxPLs present on Lp(a) and specifically on apo(a).
We demonstrate an increased inflammatory activity in the arterial wall in subjects with elevated Lp(a), who present with enhanced 18 F-FDG uptake in the arterial wall proportional to their Lp(a) levels. In analogy to the enhanced glucose consumption in inflamed tissue, arterial wall 18 F-FDG uptake has been proposed as a marker of atherogenic inflammation, supported by pre- ABR indicates arterial wall-to-blood pool ratio; CRP, C-reactive protein; IL-6, interleukin-6; Lp(a), lipoprotein(a); MFI, mean fluorescence intensity; PET, positron emission tomography; SPECT, single-photon emission computed tomography; TBR, target-to-background ratio; and TNFα, tumor necrosis factor-α. Correlation coefficients of the Spearman ρ test are shown.
TBR and ABR are imaging metrics. CRP was measured in whole plasma. TNFα and IL-6 were measured as products of monocytes after Toll-like receptor ligand challenge. CD11b, CD11c, CD29, and CD36 expression on monocytes was measured by flow cytometry as described in Methods. *P<0.06. †P<0.05. ‡P<0.001.
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ARTICLE 619 vious studies documenting 18 F-FDG uptake primarily in macrophage-rich areas in atherosclerotic plaques. 28 In addition, we report that this increased local inflammatory activity coincides with a higher accumulation rate of autologous PBMCs in the arterial wall as visualized by single-photon emission CT/CT imaging. Whereas we demonstrated previously augmented influx of PBMCs in advanced atherosclerotic plaques, 20 the present finding emphasizes that in subjects at increased risk for atherosclerotic disease because of Lp(a) elevation, PBMC accumulation in the arterial wall is enhanced significantly also at sites without plaques. The increased arterial inflammatory signal in our subjects with elevated Lp(a) cannot be attributed to differences in atherosclerotic burden for 2 reasons: The normalized wall index of the carotids on magnetic resonance imaging did not differ from that of control subjects, inflammatory measures of the arterial wall did not correlate with structural arterial wall metrics. The absence of a consistent relation between Lp(a) elevation and established surrogate markers of atherosclerotic burden observed in this and in previous studies 37, 38 implies that Lp(a) may increase CVD risk by enhancing plaque vulnerability rather than accelerating plaque burden.
To address whether intrinsic cellular activation precedes enhanced PBMC migration in Lp(a) subjects, we subsequently analyzed isolated circulating monocytes, which are key contributors to the technetium uptake by PBMCs. 21 Using ex vivo assays, we were able to recapitulate our in vivo findings. First, we found that monocytes isolated from subjects with elevated Lp(a) displayed an increased capacity to transmigrate the endothelium. Second, we observed that monocytes isolated from subjects with elevated Lp(a) have enhanced capacity to produce proinflammatory cytokines on TLR stimulation. Previous experimental studies showed that the apo(a) component of Lp(a) also was able to activate endothelial cells, 39 whereas apo(a) also colocalized with the adhesion molecule Mac-1 in the arterial wall. 40 When these data are integrated, subjects with elevated Lp(a) might be burdened by a double hit comprising activated monocytes and endothelial cells, both predisposing for increased arterial wall inflammation.
In support of a causal role for Lp(a) in driving monocyte activation, a series of in vitro experiments substantiate that high Lp(a) plasma induces monocyte activation in vitro, which is abolished after lipid-depletion, and that among the isolated lipoprotein fractions, only Lp(a) and apo(a) (particles carrying OxPL) have the capacity to induce long-term monocyte activation.
In humans, >85% of plasma lipoprotein-associated OxPLs are present on Lp(a). On Lp(a), OxPLs are present in the lipid phase [ie, removable from Lp(a) by delipidation with organic solvents] and covalently attached to apo(a). 8, 9 Here, we found 5 OxPL species on Lp(a): POVPC, PGPC, PONPC, PAzPC, and KDdiAphosphocholine, with PONPC being the most abun- , and low-density lipoprotein (LDL). OxPL, apo(a), and apolipoprotein B-100 resolved on SDS-PAGE in reducing and nonreducing conditions were detected with the use of the monoclonal antibodies E06, LPA4, and MB47 respectively. E06 immunostained apo(a) and Lp(a) but not LDL isolated from the same subject. B and C, Pretreatment with the E06 antibody (1 nmol/L) against OxPLs inhibited the increased monocyte response after priming with 8 kringle-IV (8K-IV; 0.1 µg/mL; gray bars) and subsequent challenge with Pam3cys, shown as percent of the initial priming with 8K-IV, corrected for IgM control antibody (n=6). D and E, Priming with β-glucan (5 µg/mL; positive control; black bar) and the recombinant apo(a) [r-apo(a)] construct 17 kringle (17K; 0.1 µg/mL; gray bar) induced increased cytokine production after Pam3Cys (10 µg/mL), whereas 17KΔLBS lacking OxPL (0.1 µg/mL; gray bar) did not (n=6). F and G, Priming with β-glucan (5 µg/mL positive control; black bar) and oxidizes (ox) PAPC (gray bars) increased the monocyte responsiveness compared with RPMI (negative control; white bar; n=6). IL indicates interleukin; and TNF α, tumor necrosis factor-α. ^P<0.06; *P<0.05; **P<0.01; ***P<0.001. dant. Previously, PONPC was shown to be the most abundant OxPL in the debris of distal protection devices from coronary bypass graft, carotid, and renal interventions. 41 Recombinant 17K apo(a) containing covalently bound OxPL but not 17KΔLBS r-apo(a), which lacks E06-detectable OxPL, 9 reproduced Lp(a) priming of monocyte activation. The key epitope that E06 recognizes is the phosphocholine head group when presented in the proper conformation on OxPL. Sequencing the V H and V L chains of E06 revealed that they were identical to those regions of the T15 IgA natural antibody, which has been crystallized with its antigen, the phosphocholine moiety. 42 Additional detailed lipidomic study of a large variety of lipids, oxidized lipids, and oxidized lipid adducts revealed that like T15 the IgM E06 bound only to oxidized phosphocholine containing phospholipids (eg, phosphocholine, and only when the sn2 side chain was oxidized and or adducted to a protein) but not to native PAPC, suggesting that oxidation products of the sn2 polyunsaturated fatty acids generated from oxidized PAPC appeared to generate the correct conformational epitope of the phosphocholine to allow recognition by E06. 34, 42 Here, we demonstrate that the proinflammatory effects of apo(a) can be blocked by E06. Furthermore, we show that a r-apo(a) that contains bound OxPL is capable of activating monocytes, whereas the nearly identical but mutated r-apo(a) that has lost the ability to bind OxPL does not have monocyte activation properties, indicating the necessity for OxPL to mediate monocyte activation. In aggregate, these data indicate that the OxPLs carried by Lp(a) are obligatory danger signals in eliciting the prolonged potentiation of the monocyte response in vitro.
These findings also are complementary to prior reports demonstrating that OxPLs are danger-associated molecular patterns. The phosphocholine head group on OxPLs is recognized by multiple innate pattern recognition receptors. 12 For example, both CD36 and SR-B1 bind the phosphocholine on OxPL, 33, 43 and consequently, E06 blocked the uptake of oxidized LDL by these macrophage scavengers. 44 In addition, both acute and chronic lung injury in mice has been shown to lead to the generation of OxPL in the brochiolavage fluid, which in turn caused cytokine production by macrophages that was dependent on TLR4, and E06 was capable of blocking the proinflammatory properties of the OxPL. 45 Similarly, the OxPL content of apoptotic cells was shown to induce endothelial expression of IL-8, and more recently, the OxPL-apo(a) was shown to be necessary for apo(a)-mediated upregulation of IL-8 by macrophages. 35, 36 Hence, the mechanisms by which OxPL accelerates atherosclerosis have been attributed both to mediating uptake of oxidized LDL into macrophages to generate foam cells and to a variety of proinflammatory and plaque-destabilizing processes. [11] [12] [13] In addition, recent studies suggest that such danger-associated molecular patterns/pathogen-associated molecular patterns induce long-term potentiation of their inflammatory response in vitro via epigenetic alterations. 32, 46, 47 Future studies will need to focus on elucidating how and for how long OxPL-Lp(a) induce adaptive responses of monocytes.
Whereas the present study cannot substantiate that OxPL also is a prerequisite for monocyte activation in humans in vivo, it is interesting to note that our subjects with elevated Lp(a) exhibited 4-fold higher OxPL-apoB levels (OxPL associated with all apoB lipoproteins) and even 20-fold higher OxPL-apo(a) levels [OxPL associated with Lp(a) lipoproteins] compared with subjects with normal Lp(a). This increased circulating OxPL content in subjects with elevated Lp(a) suggests that a comparable impact of OxPL may hold true in vivo. In support, we have shown previously that OxPL-apoB levels were potent predictors of progressive atherosclerosis and the risk of CVD and death in patients. [14] [15] [16] 48 It remains to be established whether lowering of Lp(a) and OxPL also will lead to a reduction in arterial wall inflammation and eventually CVD risk. Recently, an antisense-based approach was reported that specifically lowered Lp(a) levels by ≈80% and their associated OxPL-apoB and OxPL-apo(a) levels to a similar degree. 49, 50 With the development of such therapies to effectively lower Lp(a), 51 we should be able to design appropriate clinical trials to aid in dissecting the (causal) relation between Lp(a) and cellular and arterial wall inflammation. In addition to Lp(a)-lowering therapies, the present findings may provide novel targets to modulate the atherogenic impact of Lp(a). Because the OxPL content of Lp(a) seems to mediate the proinflammatory effect on monocytes, oxidation-specific epitope-targeted therapy with specific antibodies also may bear clinical potential. 52 At present, these approaches are being evaluated in experimental settings only. 53, 54 cOnclUsiOns Our findings strengthen the case for the inflammatory hypothesis of Lp(a) by addressing the increased inflammatory activity in the arterial wall, corresponding to an enhanced accumulation of activated immune cells, in which Lp(a)-associated OxPLs are obligatory intermediates.
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